A randomised clinical trial investigating the effect of rosuvastatin versus placebo in in patients with end-stage renal disease on hemodialysis
Studied treatment | rosuvastatin 10 mg daily |
Control treatment | placebo |
Patients | in patients with end-stage renal disease on hemodialysis |
Group sizes | 1391 / 1385 |
Inclusion criteria | age 50-80 years patients with end-stage renal disease receiving hemodialysis for at least 3 months |
Exclusion criteria | statin therapy within the last 6 month; expected kidney transplant within 1 year; life expectancy <1 year; history of malignancy; alanine aminotransferase >3x the ULN; uncontrolled hyperthyroidism; unexplained elevation in creatine kinase >3x the ULN |
Diabetes (%) |
Blindness | double blind | Inclusion period | jan 2003 - dec 2004 |
Follow-up duration | 3.2 y mean (max 5.6y) | Centers | |
Lost to FU | geographical localisation | ||
Primary endpoint | cardiovascular death, nonfatal MI, or nonfatal stroke | Design | Parallel groups |
PeriodeInclusion | jan 2003 - dec 2004 |
Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 2009;360:1395-407. [PMID: 19332456] link to pdf add to Mendeley
Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-407 [PMID: 19332456] link to pdf add to Mendeley
Appears in following systematic reviews: